CCN3 and aortic aneurysm

CCN3 和主动脉瘤

基本信息

  • 批准号:
    8851671
  • 负责人:
  • 金额:
    $ 39.03万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-06-01 至 2016-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The aortic wall is a highly organized and regulated structure that performs essential functions in a unique hemodynamic milieu. Maintenance of aortic wall structure and homeostasis involves interactions between major structural components and its cellular constituent - the vascular smooth muscle cell (SMC). Perturbation of these interactions secondary to genetic and/or environmental factors can lead to permanent dilatations termed aortic aneurysms (AA); a disease that accounts for 2% of deaths worldwide. Insights gleaned from clinical, pathologic, and experimental studies indicate that local inflammation of the aorta, fragmentation of the extracellular matrix, and loss of smooth muscle cells are central features in the initiation and progression AA. These lesions in both the thoracic and abdominal aorta can deteriorate resulting in dissection and /or rupture. While the molecular pathways governing AA formation remain poorly understood, accumulating evidence implicates activation of the renin-angiotensin system (RAS) as an important contributor to the pathogenesis of AA disease. However, current pharmacotherapies targeting this pathway and others have demonstrated only modest therapeutic benefit suggesting that greater insights into the pathobiology of this disease entity are required to develop effective treatments. CCN (Cyr61, Ctgf, Nov) family proteins are a group of secreted extracellular matrix-associated signaling proteins that are capable of mediating diverse biologic functions. However, the physiological functions of these proteins in the vasculature are largely unknown. Nascent observations from the applicant's laboratory identify CCN3 (a member of CCN family) as an essential regulator of AA formation. CCN3 expression was found to be strongly reduced in the rodent aorta following angiotensin II (Ang II) infusion, findings recapitulated in human AA tissues. Mice systemically deficient in CCN3 develop AA characterized by elastin fragmentation, vascular inflammation/dissection, and SMC apoptosis following Ang II infusion. Additionally, CCN3 deficiency dramatically increased the nuclear levels of NFkB, a key regulator of vascular SMC inflammation and survival. Lastly, we identify Kruppel-like factor 15 (KLF15), an essential determinant of AA formation, as an upstream regulator of CCN3 expression in SMC. Collectively, these observations provide cogent evidence implicating a previously unrecognized role for CCN3 in the pathogenesis of AA disease. To better understand the role of CCN3 in aneurysmal biology three robust and interrelated aims are proposed. In Aim 1, we will fully characterize the role of CCN3 in aortic aneurysm formation. In Aim 2, we seek to elucidate the molecular mechanism by which CCN3 deficiency leads to aortic aneurysm development. And finally, in Aim 3, we will determine the importance of CCN3 in AA formation in KLF15-KO animals. The results of these studies may provide the foundation for novel approaches to the treatment of this disease.
描述(由申请人提供):主动脉壁是一个高度组织和调节的结构,在独特的血流动力学环境中发挥重要作用。主动脉壁结构和内稳态的维持涉及主要结构成分及其细胞成分血管平滑肌细胞(SMC)之间的相互作用。继发于遗传和/或环境因素的这些相互作用的扰动可导致永久性扩张,称为主动脉瘤(AA);这种疾病占全球死亡人数的2%。从临床、病理和实验研究中收集到的见解表明,主动脉局部炎症、细胞外基质断裂和平滑肌细胞丢失是AA发生和发展的主要特征。两个胸椎的病变

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Zhiyong Lin其他文献

Zhiyong Lin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Zhiyong Lin', 18)}}的其他基金

Matricellular protein CCN3 in vascular homeostasis
基质细胞蛋白 CCN3 在血管稳态中的作用
  • 批准号:
    10504077
  • 财政年份:
    2022
  • 资助金额:
    $ 39.03万
  • 项目类别:
Matricellular protein CCN3 in vascular homeostasis
基质细胞蛋白 CCN3 在血管稳态中的作用
  • 批准号:
    10662518
  • 财政年份:
    2022
  • 资助金额:
    $ 39.03万
  • 项目类别:
Deciphering the regulatory role of matricelluar protein CCN3 in functional collateral blood flow
解读基质细胞蛋白CCN3在功能性侧支血流中的调节作用
  • 批准号:
    10594955
  • 财政年份:
    2020
  • 资助金额:
    $ 39.03万
  • 项目类别:
Deciphering the regulatory role of matricelluar protein CCN3 in functional collateral blood flow
解读基质细胞蛋白CCN3在功能性侧支血流中的调节作用
  • 批准号:
    10371083
  • 财政年份:
    2020
  • 资助金额:
    $ 39.03万
  • 项目类别:
Role of Protein Phosphatase 2A in Aortic Aneurysm
蛋白磷酸酶 2A 在主动脉瘤中的作用
  • 批准号:
    10317079
  • 财政年份:
    2019
  • 资助金额:
    $ 39.03万
  • 项目类别:
KLF15 and circadian regulation of alcohol-induced liver injury
KLF15 与酒精性肝损伤的昼夜节律调节
  • 批准号:
    9212759
  • 财政年份:
    2014
  • 资助金额:
    $ 39.03万
  • 项目类别:
KLF15 and circadian regulation of alcohol-induced liver injury
KLF15 与酒精性肝损伤的昼夜节律调节
  • 批准号:
    9000080
  • 财政年份:
    2014
  • 资助金额:
    $ 39.03万
  • 项目类别:
KLF15 and circadian regulation of alcohol-induced liver injury
KLF15 与酒精性肝损伤的昼夜节律调节
  • 批准号:
    8576602
  • 财政年份:
    2014
  • 资助金额:
    $ 39.03万
  • 项目类别:
CCN3 and aortic aneurysm
CCN3 和主动脉瘤
  • 批准号:
    8470031
  • 财政年份:
    2013
  • 资助金额:
    $ 39.03万
  • 项目类别:
CCN3 and aortic aneurysm
CCN3 和主动脉瘤
  • 批准号:
    8669158
  • 财政年份:
    2013
  • 资助金额:
    $ 39.03万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 39.03万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.03万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 39.03万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.03万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 39.03万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 39.03万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.03万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 39.03万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 39.03万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.03万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了